Tectonic Therapeutic (TECX) TD Cowen 46th Annual Health Care Conference summary

Strategic focus and pipeline overview

• Focused on developing agonist and antagonist biologics targeting GPCRs for high unmet need areas with significant market potential.

• Two clinical programs: TX45 (long-acting relaxin) in phase II for PH-HFpEF and PH-ILD, and TX2100 (APJ antagonist) in phase I for HHT.

• Robust preclinical pipeline and strong executive leadership with a track record of drug approvals.

• Well-capitalized to advance the pipeline and maintain clinical momentum.

Clinical development and trial updates

• Phase II APEX study for PH-HFpEF expects results in late 2026 or early 2027; PH-ILD phase II recently initiated.

• TX2100 phase I data expected by Q4 2024, with phase I-B and phase II studies to follow.

• Phase II PH-HFpEF study is a six-month trial with primary endpoint of PVR reduction; secondary endpoints include cardiac output and Six-Minute Walk.

• Enrollment for phase II is progressing well, with completion targeted for late 2024 or early 2025.

Mechanistic rationale and clinical evidence

• TX45 targets both IPCPH and CPCPH subpopulations, with greater unmet need in CPCPH.

• Phase I-B data showed 19% reduction in pulmonary capillary wedge pressure, 18% increase in cardiac output, and over 30% reduction in PVR.

• Durability of effect observed up to 30 days post-dose; similar durability seen in external studies.

• TX2100 demonstrated efficacy in preclinical HHT models, with improved safety and durability compared to anti-VEGF agents.